

Title (en)

NON-DIABETOGENIC THERAPY USING A 20KDA PLACENTAL GROWTH HORMONE VARIANT

Title (de)

NICHT-DIABETOGENE THERAPIE UNTER VERWENDUNG EINER 20KDA-PLAZENTALVARIANTE DES WACHSTUMSHORMONS

Title (fr)

THERAPIE NON-DIABETOGENIQUE FAISANT INTERVENIR UN VARIANT D'HORMONE DE CROISSANCE PLACENTAIRE 20KDA

Publication

EP 1778269 A4 20090923 (EN)

Application

EP 05799870 A 20050722

Priority

- US 2005026061 W 20050722
- US 59079404 P 20040723
- US 64946905 P 20050202

Abstract (en)

[origin: WO2006012525A2] Embodiments of the present invention provide improved methods of treating conditions requiring human growth hormone (hGH) therapy, whereby the beneficial effects of hGH such as growth promotion and lipolysis are retained and unwanted properties such as insulin resistance are reduced or eliminated. In particular, embodiments of this invention are directed to methods of treatment whereby the diabetogenic side effects of conventional hGH treatment are reduced. The methods include the use of the growth hormone variant; 20kDa hGH-V in the treatment of conditions that are currently treated with hGH or that have the potential to be treated with hGH.

IPC 8 full level

A61K 38/27 (2006.01)

CPC (source: EP)

A61K 38/27 (2013.01); **A61P 3/00** (2017.12); **A61P 3/04** (2017.12); **A61P 3/06** (2017.12); **A61P 3/10** (2017.12); **A61P 5/06** (2017.12); **A61P 9/04** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 11/00** (2017.12); **A61P 13/12** (2017.12); **A61P 15/00** (2017.12); **A61P 19/08** (2017.12); **A61P 19/10** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12)

Citation (search report)

- [X] WO 02101002 A2 20021219 - GENODYSEE [FR], et al
- [X] EP 0753307 A2 19970115 - MITSUI TOATSU CHEMICALS [JP]
- [A] EP 0356107 A2 19900228 - LILLY CO ELI [US]
- [X] CULLER F L ET AL: "Comparison of the acute metabolic effects of 22,000-dalton and 20,000-dalton growth hormone in human subjects", HORMONE AND METABOLIC RESEARCH, THIEME-STRATTON, STUTTGART, DE, vol. 20, no. 2, 1 February 1988 (1988-02-01), pages 107 - 109, XP002099021, ISSN: 0018-5043
- [PX] VICKERS ET AL: "P-01 THE 20kDa PLACENTAL GH-V LACKS THE DIABETOGENIC AND LACTOGENIC ACTIVITIES OF GH-N WHILST RETAINING ANTI-LIPOGENIC ACTIVITY", GROWTH HORMONE AND IGF RESEARCH, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 16, 1 November 2006 (2006-11-01), pages S27, XP005832058, ISSN: 1096-6374
- See references of WO 2006012525A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2006012525 A2 20060202; **WO 2006012525 A3 20060824**; EP 1778269 A2 20070502; EP 1778269 A4 20090923; JP 2008507559 A 20080313

DOCDB simple family (application)

US 2005026061 W 20050722; EP 05799870 A 20050722; JP 2007522809 A 20050722